The US FDA on Thursday authorised Pfizer booster for 16- and 17-year-olds, news agency Reuters reported. The FDA authorized booster shots of the COVID-19 vaccine from Pfizer and BioNTech to those aged 16 and 17, as public health officials have urged Americans to get the additional shots on concerns about the new Omicron variant of the virus.Also Read – Suriya Starrer Jai Bhim Tops The Most Searched Films, Shershaah Stands at Number Two
Earlier, Pfizer had said that a booster dose of its COVID-19 vaccine may offer important protection against the new omicron variant even though the initial two doses appear significantly less effective. Pfizer and its partner BioNTech said that while two doses may not be protective enough to prevent infection, lab tests showed a booster increased by 25-fold people’s levels of virus-fighting antibodies against the omicron variant. Also Read – India Extends Suspension of Scheduled International Commercial Flights Services Till January 31
Blood samples taken a month after a booster showed people harboured levels of omicron-neutralising antibodies that were similar to amounts proven protective against earlier variants after two doses. Also Read – India Removes Singapore From ‘At-Risk’ List Amid Omicron Threat | Important Details Here
Scientists don’t yet know how big a threat the omicron variant really is. Currently the extra-contagious delta variant is responsible for most of the COVID-19 cases in the US and other countries.
But the omicron variant, discovered late last month, carries an unusually large number of mutations and scientists are racing to learn how easily it spreads, whether it causes illness that is more serious or milder than other coronavirus types — and how much it might evade the protection of prior vaccinations.
Pfizer’s findings, announced in a press release, are preliminary and haven’t yet undergone scientific review. But they’re the first from a vaccine maker examining whether the booster doses that health authorities are urging people to get may indeed make an important difference.
Scientists have speculated that the high jump in antibodies that comes with a third dose of COVID-19 vaccines might be enough to counter any decrease in effectiveness.
Pfizer and BioNTech already are working to create an omicron-specific vaccine in case it’s needed. Antibody levels predict how well a vaccine may prevent infection with the coronavirus but they are just one layer of the immune system’s defenses.
Pfizer said two doses of the vaccine should still protect against severe disease, because the mutations in omicron don’t appear to hamper one of those other defenses, T cells that fight the virus after infection sets in.
“Although two doses of the vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from these preliminary data that protection is maximised with a third dose of our vaccine,” Pfizer CEO Albert Bourla said in a statement.
Pfizer’s announcement had an immediate impact on US markets. Futures that had pointed to a lower open reversed course in seconds and swung solidly to the positive with the Dow jumping almost 200 points.